LNAI

Lunai Bioworks Inc. (LNAI) - Q1 2026 (Ended Sept 30, 2025) Summary

Business Context and Reporting Period

This Form 10-Q covers the three-month period ended September 30, 2025. Lunai Bioworks Inc. (formerly Renovaro Inc.) is an AI-driven platform for precision medicine, diagnostics, and biodefense. During the quarter, the Company changed its name from Renovaro Inc. to Lunai Bioworks Inc. and completed the acquisition of BioSymetrics, Inc. Conversely, the Company deconsolidated its subsidiary Gedi Cube B.V. following a bankruptcy declaration in Amsterdam on September 2, 2025. The Company operates as a pre-revenue entity focused on oncology, infectious diseases, and AI-driven drug discovery.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income Turnaround: The Company reported a net income of $2.82 million compared to a net loss of $44.21 million in the prior year. This shift was driven primarily by a $12.02 million gain on the bankruptcy of subsidiary Gedi Cube B.V. and a $47.61 million reduction in goodwill impairment charges recorded in the prior year.
• Operating Expenses: Total operating expenses decreased by 94% to $3.31 million. This reduction is largely due to the absence of the $47.6 million goodwill impairment from the prior period and a 55% decrease in general and administrative expenses.
• Debt Restructuring: The Company executed a significant debt-for-equity exchange in July 2025, converting approximately $9.7 million in secured notes into $16.1 million of convertible notes, which were immediately converted into 5.36 million shares of common stock. This resulted in a $6.33 million loss on extinguishment of debt.
• Asset Base: Total assets decreased to $6.96 million from $8.23 million, primarily due to the deconsolidation of Gedi Cube B.V. and the impairment of long-lived assets.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states substantial doubt about the Company's ability to continue as a going concern. With a working capital deficit of $18.9 million and cash of only $624,808, the Company is dependent on additional equity or debt financing to fund operations. Failure to secure funding could lead to a suspension of operations or bankruptcy.
• Legal Proceedings: The Company is involved in multiple significant legal matters:
  • Securities Class Action: A settlement has been preliminarily approved by the court regarding the "Chow Action" alleging false statements regarding commercial prospects.
  • Derivative Litigation: Multiple shareholder derivative actions (Koenig, Solak, Midler) are pending or stayed, with a proposed settlement filed for preliminary approval.
  • IP Disputes: The Company is suing former partners (G Tech Bio, SRI) alleging fraud and fabrication of study results, seeking recovery of approximately $25 million. Conversely, these partners have filed cross-claims seeking termination of licenses.
  • Investor Rights: Litigation with Weird Science LLC regarding registration rights remains active, with some claims dismissed and others pending appeal.
• Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, citing a material weakness due to inadequate resources to address complex accounting matters.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $624,808 cash balance against the $18.9 million working capital deficit and ongoing burn rate.
• Financing Plans: Confirm the status of any pending equity or debt financing required to avoid operational suspension.
• Legal Settlements: Monitor the final court approval and terms of the Securities Class Action and Derivative Litigation settlements.
• Debt Obligations: Review the terms of remaining notes payable, including the $1.04 million in notes payable and $866,661 in related party notes.
• Internal Controls: Assess the timeline and plan for remediation of the identified material weakness in internal controls over financial reporting.